Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2023 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Real-World Evidence
Home
Real-World Evidence
Real-World Evidence
Type here to filter the list
16: Clinical Outcome of Patients with Primary Metastatic Renal Cell Carcinoma Carefully Selected for Cytoreductive Nephrectomy: A Nationwide Real-World Data
Favorite
17: Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma (RCC) in England
Favorite
18: Optimal Duration of Frontline Immunotherapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Favorite
19: Real World Experience (RWE) of Ipilimumab and Nivolumab compared to Pembrolizumab and Axitinib in Advanced Renal Cell Carcinoma (RCC)
Favorite
20: A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology
Favorite
21: Real-world recurrence patterns in Danish renal cell carcinoma patients
Favorite
22: Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy
Favorite
23: Role of cytoreductive nephrectomy in metastatic RCC, single institution experience
Favorite
24: Real-world outcomes of nivolumab (NIVO) + ipilimumab (IPI) in patients with previously untreated clear cell advanced renal cell carcinoma (aRCC) in France.
Favorite
25: 4-weekly avelumab administration plus axitinib in patients with metastatic renal cell carcinoma: A single centre analysis of patient outcomes
Favorite
26: Anticoagulant treatment and thromboembolic events prior to diagnosis of renal cell carcinoma: Impact on stage distribution
Favorite